HIV-1 infection prevention
Infectious disease · 2016–2016
1decision
1medicine
1carried consumer input
92individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| emtricitabine/tenofovir disoproxil fumarate Oral pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at substantial risk. | Jul 2016 | Not recommended | 92 individuals |
What the PBS pays
$184M in government benefit over 2024–25, across 193,107 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| emtricitabine/tenofovir disoproxil fumarate | $183.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.